R Squared Ltd Acquires Shares of 5,170 GSK plc (NYSE:GSK)

R Squared Ltd bought a new position in shares of GSK plc (NYSE:GSK) during the fourth quarter, according to its most recent filing with the SEC. The fund bought 5,170 shares of the pharmaceutical company’s stock, valued at approximately $175,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in GSK. FMR LLC raised its position in GSK by 8.3% in the third quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock worth $1,185,885,000 after acquiring an additional 2,224,345 shares during the period. Fisher Asset Management LLC raised its holdings in shares of GSK by 4.9% in the 3rd quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock worth $759,425,000 after purchasing an additional 870,449 shares during the period. Clifford Capital Partners LLC lifted its stake in GSK by 14.3% in the third quarter. Clifford Capital Partners LLC now owns 409,669 shares of the pharmaceutical company’s stock valued at $16,747,000 after purchasing an additional 51,378 shares during the last quarter. Cerity Partners LLC grew its holdings in GSK by 61.8% during the third quarter. Cerity Partners LLC now owns 433,628 shares of the pharmaceutical company’s stock valued at $17,728,000 after purchasing an additional 165,556 shares during the period. Finally, Natixis Advisors LLC increased its position in GSK by 20.0% in the third quarter. Natixis Advisors LLC now owns 500,495 shares of the pharmaceutical company’s stock worth $20,460,000 after buying an additional 83,433 shares during the last quarter. 15.74% of the stock is owned by hedge funds and other institutional investors.

GSK Stock Down 0.1 %

GSK stock opened at $35.06 on Thursday. The stock has a 50-day simple moving average of $33.98 and a two-hundred day simple moving average of $37.75. GSK plc has a twelve month low of $31.72 and a twelve month high of $45.92. The firm has a market capitalization of $72.67 billion, a PE ratio of 22.77, a PEG ratio of 1.31 and a beta of 0.63. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. StockNews.com cut GSK from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, January 21st. Jefferies Financial Group downgraded shares of GSK from a “buy” rating to a “hold” rating and dropped their price objective for the company from $53.00 to $39.50 in a report on Tuesday, November 12th. Guggenheim downgraded shares of GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Finally, Deutsche Bank Aktiengesellschaft cut shares of GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Six research analysts have rated the stock with a hold rating, one has issued a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, GSK has an average rating of “Moderate Buy” and an average target price of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.